A prospective multicenter observational post authorization safety sub-registry to characterize the long-term safety profile of commercial use of eliglustat (Cerdelga®) in adult patients with Gaucher disease (ELISAFE)

11/02/2016
16/02/2026
EU PAS number:
EUPAS11998
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

OBS14099 protocol_PASS_PRAC03_23Aug2016

English (626.47 KB - PDF) View document
Updated protocol

rdct-obs14099-16-1-1-pass-amended-protocol04-pdfa

First published: 22/02/2024
English (640.63 KB - PDF) View document
Study results
Study report
Abstract of study report

rdct-obs14099-csr-abstract.pdf

English (372.67 KB - PDF) View document
Other information